Acidez Estomacal

5-HTP is the direct precursor to serotonin and has been studied for anxiety, panic disorder, and depression. Clinical trials show it can reduce anxiety symptoms by raising serotonin levels. It is reviewed among nutritional supplements with anxiolytic evidence in peer-reviewed systematic reviews. Traditional use derives from Griffonia simplicifolia seeds in West African medicine.

Antianxiety activity has been identified in preclinical studies of A. spectabilis and is confirmed in multiple pharmacological reviews. In vivo studies using elevated plus-maze models tested Abies extracts for anxiolytic effects. The 2021 comprehensive review lists antianxiety among confirmed in vivo bioactivities.

Catecholamine depletion studies show tyrosine availability influences anxiety-adjacent arousal states under acute stress. AMPT-induced catecholamine depletion in SAD remission patients caused depressive relapse including anxious features. One military SERE-school trial found tyrosine increased anger ratings under extreme stress but had no clear anxiolytic effect. Direct anxiolytic RCT evidence for NALT is absent.

Animal studies show A. muciniphila supplementation reduces anxiety-like behavior, correlating with reduced neuroinflammatory markers and modulation of the HPA axis. A 2024 systematic meta-analysis of 15 mouse studies confirmed anti-anxiety effects. In a rodent Alzheimer's model, A. muciniphila reduced both anxiety-related behavior and cognitive impairment. Human clinical data are associative only; no anxiety-specific RCT in humans has been published.

DHA from algal oil is linked to reduced anxiety through modulation of neurotransmitter pathways. A 12-month RCT found that DHA+EPA supplementation reduced anxiety scores specifically in APOE ε4 carriers with mild cognitive impairment. Animal and epidemiological data also associate low DHA status with heightened susceptibility to stress and anxiety.

Anchovies are a rich source of EPA and DHA, omega-3 fatty acids that have been investigated for anxiolytic effects. An RCT found that n-3 PUFA supplementation alleviated anxiety symptoms in drug-naïve depressed patients. The proposed mechanism involves modulation of neuronal membrane fluidity, neurotransmission, and neuroinflammation.

Apigenin is a flavonoid found in chamomile, parsley, and many other plants that binds to GABA-A benzodiazepine receptors, producing anxiolytic effects in preclinical and clinical studies. It is the primary anxiolytic compound in chamomile, and clinical trials of chamomile extract standardized to apigenin have demonstrated anxiolytic efficacy in GAD.

Multiple randomized controlled trials and meta-analyses demonstrate that ashwagandha root extract significantly reduces anxiety and perceived stress scores. A 2024 meta-analysis of 9 RCTs (558 patients) showed significant reductions on the Hamilton Anxiety (HAM-A) and Perceived Stress Scale. Typical studied doses range from 240–600 mg/day of standardized extract. Its active withanolides are believed to modulate the HPA axis and reduce cortisol.

Multiple preclinical studies document A. racemosus attenuates anxiety-like behavior in animal models via GABAergic, serotonergic, and HPA axis pathways. PubMed-indexed reviews categorize anxiety among the neurological conditions for which asparagus-based nutraceuticals show adaptogenic and neuroprotective activity with clinical settings cited. Traditional Ayurvedic use as a nervine tonic is well-established.

A 12-week RCT (n=100) using B. coagulans BCP92 showed significant reduction in anxiety levels in IBS patients. An 8-week pilot RCT (n=79) with W. coagulans BC99 showed HAMA scores reduced by 5.53 points more than placebo, with regulation of inflammatory cytokines and neurotransmitter levels. Animal studies further support anxiolytic effects via the gut-brain axis.

Baicalin is the primary flavonoid of Baikal skullcap (Scutellaria baicalensis) with documented anxiolytic activity via GABA-A receptor binding. Preclinical studies demonstrate robust anxiolytic effects. It is among the active constituents proposed to underlie the traditional use of skullcap herbs for anxiety. Human clinical data are emerging.

Bananas contain tryptophan, vitamin B6, magnesium, and zinc—nutrients linked to serotonin synthesis and anxiety modulation. A comprehensive review of 18 studies found most experimental trials reported positive antianxiety effects, though clinical trial results were inconsistent. Vitamin B6, found abundantly in bananas, has shown anxiolytic effects in at least one RCT.

Preclinical studies show B. bifidum supplementation improves anxiety-like behavior in rodents subjected to chronic intestinal inflammation. Genus-level evidence from epidemiological and interventional studies links Bifidobacterium abundance to stress and anxiety outcomes via gut-brain axis pathways. B. bifidum specifically has been noted in rodent models for anxiolytic effects.

B. breve A-1 significantly improved anxiety scores in schizophrenia patients in a clinical proof-of-concept study. B. breve M-16V in a double-blind, placebo-controlled RCT improved mood and sleep in participants with high state anxiety and reduced stress-associated heart rate. These effects are mediated through gut-brain axis signaling involving GABA-related metabolites and autonomic nervous system modulation.

Multiple RCTs show B. longum strains reduce anxiety-related measures in humans. Strain NCC3001 reduced anxiety scores in IBS patients and correlated with reduced fearful stimulus reactions. Strain 1714 reduced self-reported anxiety in response to acute stress in healthy adults. The mechanism appears to involve the vagus nerve and gut-brain axis.

Preclinical studies show Platycladi Semen (biota seed) has measurable anxiolytic effects in rodent models. Both its aqueous extract and fatty oil reduced anxiety behaviors in CUMS-stressed mice. Proposed mechanisms involve regulation of lipid metabolism, neuroactive ligand-receptor interactions, and modulation of monoamine pathways. No human clinical trials have been published.

Black cohosh (Actaea racemosa) has clinical evidence primarily for anxiety and mood symptoms associated with menopause, where multiple RCTs show significant reduction in anxiety, hot flashes, and depression. It is listed among promising herbs for anxiety in systematic reviews of herbal medicine. Mechanisms include serotonergic and dopaminergic modulation rather than phytoestrogenic effects.

Two placebo-controlled human trials found that N. sativa seed (500 mg once or twice daily for 4–9 weeks) reduced anxiety scores in healthy adolescents and elderly subjects. Mechanistic studies implicate antioxidant activity, GABAergic modulation, and thymoquinone's effects on neurotransmitter systems.

Multiple preclinical studies show B. falcatum extract produces anxiolytic-like effects in rat models of restraint stress, improving performance in the elevated plus maze. These effects are linked to HPA axis modulation and central adrenergic pathways. No human clinical trials specifically for anxiety have been published for B. falcatum isolate.

A clinical study of ButyraGen (a tributyrin-containing supplement) reported a 9.29% higher improvement in anxiety rates versus placebo. Mechanistically, butyrate modulates the gut-brain axis by reducing neuroinflammation and influencing cortisol and neurotransmitter pathways. The evidence is preliminary—most human data involve small studies and the tributyrin-specific anxiolytic RCT literature is very thin.

Clinical and preclinical evidence links gut butyrate status to anxiety via the gut-brain axis. A human RCT of a butyrate-generating supplement showed significant improvements in anxiety markers. Reduced SCFA-producing bacteria are consistently found in individuals with anxiety disorders.

Seed extracts of Caesalpinia crista have demonstrated anxiolytic activity in preclinical rodent models. Studies using staircase and elevated plus-maze (EPM) models showed dose-dependent anxiolytic effects. No human clinical trials have been conducted.

Caffeine has well-documented anxiogenic effects, particularly at higher doses, supported by multiple clinical trials and meta-analyses. It acts by blocking adenosine receptors, increasing sympathetic tone and circulating catecholamines. A 2024 PMC meta-analysis found that high-dose caffeine (≥400 mg/day) significantly elevated anxiety risk (SMD=2.86) compared to lower doses. Reducing caffeine intake has been associated with improvements in anxiety symptoms in clinical practice.

Clinical evidence supports a role for omega-3 DHA and EPA in reducing anxiety symptoms, particularly in clinical populations. A meta-analysis of 19 clinical trials showed stronger benefits in participants with clinical-level anxiety. An RCT of drug-naive MDD patients found omega-3s improved anxiety symptoms significantly.

California poppy has the strongest clinical evidence base for anxiety among its indications. A double-blind, randomized, placebo-controlled trial in 264 patients with mild-to-moderate generalized anxiety found a combination of Eschscholzia californica, hawthorn (Crataegus oxyacantha), and magnesium was significantly more effective than placebo over 3 months (Hanus et al., Curr Med Res Opin 2004). Animal studies also confirm anxiolytic activity at doses ≥25 mg/kg. The herb is sold as an anxiolytic in pharmacies across several European countries.

Multiple preclinical studies demonstrate that β-caryophyllene (BCP) produces anxiolytic-like effects via CB2 receptor activation. A small human inhalation RCT (n=48) found BCP significantly reduced STAI anxiety scores on both sub-scales compared to an odorless control. The evidence base remains predominantly animal/preclinical, with limited human data.

A randomized, triple-blind, placebo-controlled crossover clinical trial found that celery seed extract (1.34 g/day for 4 weeks) significantly reduced anxiety scores in hypertensive patients. The active constituent 3-n-butylphthalide (NBP) is thought to modulate stress hormones. Evidence is preliminary but human-level.

Centella asiatica (Gotu kola) has a double-blind, placebo-controlled RCT demonstrating reduction in acoustic startle response (an anxiety biomarker) in healthy subjects, as well as a clinical study in GAD patients with positive outcomes. Triterpenoids modulate GABA-A receptors and reduce corticosterone. Traditional use in Ayurvedic and Chinese medicine for anxiety spans millennia.

Centella triterpenes (asiaticoside, madecassoside, asiatic acid, madecassic acid) are the primary bioactive fraction of Centella asiatica (Gotu kola) responsible for anxiolytic activity. They modulate GABA-A receptors and reduce corticosterone. Clinical trials of Centella asiatica standardized to these triterpenes underpin the anxiety evidence base for Gotu kola.

Chamomile (Matricaria recutita) has RCT evidence for reducing anxiety symptoms, particularly in GAD. A landmark long-term RCT demonstrated that chamomile extract significantly reduced relapse of GAD after sustained remission. Apigenin, its primary flavonoid, binds GABA-A receptors with anxiolytic properties. It is among the most historically widespread herbal anxiolytics.

Chrysin exerts anxiolytic-like effects in rodent models primarily through positive allosteric modulation of GABAA receptors at the benzodiazepine binding site. Effects are blocked by flumazenil and picrotoxin, confirming GABAergic mechanism. Serotonergic system involvement is also documented. All robust evidence remains preclinical; no completed human RCTs have established efficacy in anxiety disorders.

Clinical trials demonstrate that inhalation of Citrus sinensis essential oil reduces anxiety in dental patients and healthy volunteers exposed to anxiogenic situations. A 2018 review in Evidence-Based Complementary and Alternative Medicine analyzed nine clinical studies and confirmed anxiolytic effects across multiple conditions. The proposed mechanism involves nitrergic neurotransmission and olfactory-serotonergic system interaction.

EPA and DHA reduce neuroinflammation and support neurotransmitter balance implicated in anxiety. Observational data associate omega-3 status with lower anxiety prevalence. Controlled studies show omega-3 supplementation at ≥2 g/day reduces anxiety symptoms, particularly in stressed populations.

Animal studies demonstrate that daidzin (DZN) produces anxiolytic effects in mice, evidenced by increased locomotor behaviors in anxiety models. The proposed mechanism involves positive allosteric modulation of GABAA receptor α2 and α3 subunits. No human clinical trials have yet been conducted.

Observational studies associate lower circulating DHA with higher rates of anxiety disorders, and mechanistic evidence points to DHA's role in neuronal membrane function, neurotransmission, and neuroinflammation. A meta-analysis of omega-3 RCTs identified anxiolytic potential for EPA and DHA combined. Evidence is strongest for EPA-dominant formulations, and DHA-specific anxiolytic effects in RCTs remain modest and preliminary.

DHA, alongside EPA, modulates neuronal membrane properties, receptor expression, and neurotransmission in ways that may reduce anxiety symptoms. Meta-analyses of RCTs show mixed but generally positive signals for omega-3 PUFAs on anxiety. DHA's anxiolytic potential is supported by its anti-inflammatory and pro-resolving activity in the brain. EPA appears to have a larger independent anxiolytic effect, though DHA contributes mechanistically.

A proprietary E. angustifolia root extract (EP107) has been evaluated in multiple double-blind, placebo-controlled human trials for anxiolytic effects. One RCT showed significant reductions in state anxiety scores versus placebo; another found improvements in psychic anxiety (HADS-A) but mixed results on somatic measures. The proposed mechanism involves alkamide interactions with CB1 receptors and inhibition of FAAH, enhancing anandamide signaling. Evidence is preliminary and preparation-specific.

Multiple preclinical studies show EGCG reduces anxiety-like behavior via anti-inflammatory and neuroprotective mechanisms in hippocampal tissue. A small 8-week randomized, double-blind, placebo-controlled human trial in schizophrenia/bipolar disorder patients measured anxiety symptoms using the Hamilton Rating Scale-Anxiety. Both EGCG and placebo groups showed reductions, but EGCG's specific anxiolytic signal was not statistically differentiated from placebo.

EPA has been investigated for anxiolytic effects in clinical trials alongside its better-established antidepressant properties. A 2023 systematic review and meta-analysis found EPA-predominant omega-3 supplementation reduced anxiety severity in adults. Mechanisms include modulation of neuroinflammation, neurotransmitter signaling, and HPA-axis activity.

EPA-dominant omega-3 formulations have demonstrated anxiolytic effects in clinical trials, with EPA identified as the more bioactive component compared to DHA. A 2018 meta-analysis of 19 RCTs found omega-3 PUFAs, especially those high in EPA, significantly reduced anxiety symptoms. Proposed mechanisms include modulation of neuroinflammation and HPA axis regulation.

A preclinical rodent study (ResearchGate, Anxiolytic effect of Ferula assafoetida L.) demonstrated dose-dependent anxiolytic and mild sedative effects of asafoetida extract using elevated plus-maze and hole-board tests, with comparison against diazepam. Traditional use across Ayurvedic, Unani, and Iranian medicine also documents asafoetida as a sedative and nervine. No controlled human clinical trials for anxiety alone have been published.

Preclinical studies show fisetin reduces anxiety-like behavior in rodent models via suppression of hippocampal and prefrontal cortex neuroinflammation (TNF-α, IL-1β, IL-6) and modulation of the HPA axis. It also attenuated anxiety comorbid with neuropathic pain in mouse models. No human clinical trials exist to date.

Clinical and observational evidence suggests omega-3 PUFAs from fish oil may reduce anxiety symptoms, particularly when EPA predominates. A well-cited RCT in medical students found that omega-3 supplementation significantly reduced self-reported anxiety versus placebo. Mechanistically, omega-3s appear to modulate HPA-axis activation and inflammatory pathways implicated in anxiety. Evidence is promising but still limited by small sample sizes in individual trials.

Preclinical studies show Poria cocos water-soluble polysaccharides modulate anxiety-like behavior via the gut-brain axis, increasing serotonin, dopamine, and GABA levels. Pachymic acid, a key triterpene, interacts with GABA-A receptors and promotes serotonin release. Traditional TCM use for 'calming the Shen' aligns with these findings. Human clinical evidence remains limited.

GABA is the primary inhibitory neurotransmitter in the brain, and supplemental GABA has been studied in clinical trials for anxiety and stress reduction. Several small RCTs and a systematic review report anxiolytic effects, particularly at doses of 100–300 mg. Oral GABA bioavailability and CNS penetrance remain areas of ongoing research.

Animal studies show gamma oryzanol exerts anxiolytic effects by modulating the monoaminergic system in the amygdala. A 2020 PMC study found it alleviates high-fat-diet-induced anxiety-like behaviors through downregulation of dopamine and neuroinflammation. A separate restraint-stress study found decreased corticosterone via upregulation of the central monoaminergic system.

A pilot RCT in breast cancer patients found that Ganoderma lucidum spore powder significantly reduced self-reported anxiety scores alongside fatigue improvements. Preclinical data and a Cochrane-style systematic review protocol under development further support anxiolytic potential. Evidence remains preliminary and largely confined to disease-specific populations.

Gardenia fruit (Fructus Gardeniae) and its constituent geniposide show anxiolytic activity in preclinical models. The classical Kampo formula kamishoyosan, which contains Gardenia jasminoides, has been studied clinically and found to ease anxiety in menopausal women comparably to paroxetine. The Zhi Zi Chi decoction, a Gardenia-based TCM formula, modulates the gut–brain axis to reduce anxiety-like behavior in stress models.

Fructus Gardeniae (FG) has demonstrated anxiolytic-like effects in preclinical rodent models, primarily by modulating neuroinflammation and gut-brain axis signaling. In a rat model of sleep-deprivation-induced anxiety, FG reduced pro-inflammatory cytokines (TNF-α, IL-1β) in the hippocampus and restored gut microbiota balance, correlating with reduced anxiety-like behavior in open-field and elevated plus-maze tests. Human clinical evidence remains absent.

Gastrodia elata (GE) and its primary bioactive gastrodin have demonstrated anxiolytic effects in preclinical models via modulation of dopamine, serotonin, and GABAergic systems. Animal studies show reduction of anxiety-like behaviors and corticosterone levels. Human RCT data is limited, but mechanistic evidence from multiple in vivo studies is consistent.

Multiple randomized controlled trials support geranium essential oil aromatherapy for reducing anxiety. Studies in laboring women, surgical patients, and myocardial infarction patients consistently show significant reductions in anxiety scores. Geranium is thought to act via the limbic system and hypothalamic-pituitary-adrenal axis.

Ginkgo biloba (EGb 761 standardized extract) has shown anxiolytic activity in clinical trials, primarily in patients with cognitive impairment, where it reduced anxiety and depression symptoms significantly vs. placebo. Preclinical studies in rodents demonstrate anxiolytic effects via ginkgolide-A. It modulates monoaminergic neurotransmission, inhibits norepinephrine reuptake, and has anti-inflammatory effects.

Glutamate and its metabolic relationship to GABA (via glutamic acid decarboxylase) are mechanistically central to anxiety disorders. Clinical studies and genetic analyses have linked variants in GAD genes to generalized anxiety, panic disorder, social phobia, and neuroticism. Neuroimaging research has found altered glutamate/glutamine ratios in the prefrontal cortex and other brain regions in anxious individuals.

Glycine functions as a key inhibitory neurotransmitter in the CNS via glycine-gated chloride channels, and clinical data show improvement in anxiety symptoms including anxious mood, tension, and sleep disturbance during glycine therapy. A randomized placebo-controlled study demonstrated efficacy for mild anxiety in adjustment disorder. Emerging receptor research (GPR158/mGlyR) positions glycine signaling as a direct modulator of mood-related brain circuits.

Animal research demonstrates LBP reduces anxiety-like behaviors in rodent models. A 2008 human RCT found improved feelings of calmness in goji juice consumers, and a meta-analysis of four RCTs confirmed this effect. The anti-neuroinflammatory and antioxidant properties of LBP provide mechanistic plausibility, though dedicated anxiety RCTs in humans are lacking.

Gotu kola (Centella asiatica) has both traditional Ayurvedic use and clinical trial evidence for anxiety. A double-blind, placebo-controlled trial in healthy subjects demonstrated reduced acoustic startle response—a validated anxiety biomarker—following Gotu kola administration. A clinical study in GAD patients found it effective. Its triterpenoids modulate GABA-A receptors and reduce corticosterone.

A randomized, double-blind, placebo-controlled trial in 155 adults aged 50–70 found that 950 mg Greek Mountain Tea (GMT) significantly reduced state anxiety after 28 days compared to both placebo and an active Ginkgo biloba control. Preclinical data show S. scardica extracts act as triple monoamine reuptake inhibitors (serotonin, noradrenaline, dopamine), a mechanism consistent with anxiolytic action. Animal models further confirm reduced behavioral anxiety following GMT supplementation.

Multiple human RCTs and systematic reviews support green tea's anxiolytic properties, attributable primarily to L-theanine and its interaction with EGCG. A 2025 systematic review of 13 RCTs found 6 studies reporting improvements in anxiety symptoms. A human clinical trial in 81 healthy subjects showed significant reductions in State-Trait Anxiety Inventory (STAI) scores after 2 weeks of powdered green tea consumption. Evidence is promising but effect sizes vary and larger trials are needed.

Griffonia simplicifolia is the primary botanical source of 5-HTP and is used in traditional West African medicine. As the commercial source for 5-HTP supplementation, it shares the clinical evidence base for 5-HTP in anxiety and mood disorders. Seed extracts raising serotonin precursor availability have been clinically studied for anxiety and panic.

Ho wood's primary constituent linalool (~95–99%) has demonstrated anxiolytic effects in multiple preclinical studies via GABAergic modulation. Inhaled linalool significantly increased time spent in open/light areas in mouse models compared to controls. Traditional aromatherapy use of ho wood for calming and reducing anxiety is also well-documented.

Honokiol is a bioactive lignan from Magnolia bark with clinically relevant GABA-A receptor modulation producing anxiolytic effects. It is co-active with magnolol in Relora (Magnolia/Phellodendron extract), which has human evidence for anxiety and cortisol reduction. Preclinical studies confirm robust, non-sedating anxiolytic activity. Traditional Chinese medicine use for anxiety-adjacent conditions is extensive.

Preclinical studies document anxiolytic-relevant effects of Aegle marmelos extracts via central nervous system pathways. Multiple published reviews and primary studies identify anxiety as a neurological area where AM shows mechanistic activity, attributed to its serotonergic modulation and anti-neuroinflammatory properties.

Inositol has clinical trial evidence for anxiety disorders including panic disorder and OCD. Multiple RCTs have shown it reduces panic attack frequency and severity. It is a second messenger precursor for serotonin, acetylcholine, and other neurotransmitters. It is reviewed among evidence-based nutritional supplements for anxiety in peer-reviewed systematic literature.

A 2019 clinical study found that jiaogulan supplementation reduced anxiety proneness in subjects under chronic psychological stress, as measured by a decrease in State-Trait Anxiety Inventory (T-STAI) scores. Animal models corroborate anxiolytic effects of gypenosides. Traditional use as an adaptogen in southern China also emphasized its role in stress resilience.

Multiple small RCTs and a pharmaco-fMRI study provide preliminary human evidence for kanna's anxiolytic effects. The standardized extract Zembrin (25 mg) attenuated amygdala reactivity to fearful stimuli and reduced amygdala–hypothalamus coupling in a double-blind crossover study. A 2020 placebo-controlled study in healthy volunteers found a single 25 mg dose ameliorated experimentally induced anxiety. However, a 2023 systematic review and meta-analysis of four RCTs (n=117) found no statistically significant effect on anxiety outcomes (RR 1.01; p=0.98).

Kava (Piper methysticum) has multiple placebo-controlled trials and systematic reviews supporting its anxiolytic effect, particularly for generalized and subthreshold anxiety. Kavalactones modulate GABA-A receptors and inhibit reuptake of noradrenaline and dopamine. A meta-analysis of 5 clinical trials (n=330) found a risk ratio of 1.50 (95% CI 1.12–2.01) in favor of kava over placebo. Evidence is mixed for DSM-IV-diagnosed GAD specifically.

Kavalactones are the primary bioactive compounds of kava (Piper methysticum) responsible for its anxiolytic effects. They directly potentiate GABA-A receptors and inhibit norepinephrine reuptake. Multiple clinical trials studying standardized kava extracts (delivering defined kavalactone content) demonstrate anxiolytic effects. The evidence base for kavalactones mirrors the kava evidence base.

The same 2025 RCT in MDD patients that showed antidepressant effects also found that anxiety and distress scores on the DASS-21 scale decreased significantly in the krill oil group compared to baseline (p<0.001). Animal data in senescence-accelerated mice show krill oil reduces anxiety-like behavior. Evidence is preliminary and largely co-reported with depression outcomes.

L-arginine, in combination with L-lysine, has RCT evidence for reducing anxiety and cortisol responses in high-trait-anxiety individuals. Alone, arginine modulates nitric oxide and HPA axis function relevant to stress and anxiety. A systematic review of nutritional supplements for anxiety reviewed the L-lysine + L-arginine combination among clinical anxiolytic treatments.

NAC (the acetylated form of L-cysteine) has been investigated in anxiety disorders primarily through its ability to modulate glutamate homeostasis and reduce neuroinflammation. A 2015 systematic review found preliminary evidence for NAC in anxiety disorders, though larger confirmatory trials are still needed. Clinical trial data are mixed and most studies are underpowered.

Clinical trials show that 3 g of glycine taken before bedtime significantly reduces self-reported anxiety levels the following morning. Glycine acts as an inhibitory neurotransmitter, dampening neural excitability via strychnine-insensitive glycine receptors. Evidence comes from small controlled studies in individuals with poor sleep and insomniac tendencies.

L-histidine is the sole biosynthetic precursor of brain histamine, a neurotransmitter involved in anxiety regulation. Animal studies show that insufficient histidine intake reduces brain histamine and produces anxiety-like behaviors. Pharmacological research in rodents confirms that peripheral L-histidine administration dose-dependently induces anxiogenic effects via histamine H1 receptors. Human clinical data specific to anxiety outcomes remain limited.

L-lysine, an essential amino acid, has RCT evidence for reducing anxiety symptoms, particularly in combination with L-arginine. Clinical trials demonstrate that L-lysine supplementation reduces trait anxiety and cortisol responses to stress, possibly by acting as a partial serotonin receptor antagonist. A systematic review identified lysine monotherapy and L-lysine + L-arginine combination among reviewed anxiolytic treatments.

In the Miyake et al. 2014 RCT, L-ornithine (400 mg/day, 8 weeks) significantly reduced POMS tension-anxiety subscores in healthy workers with mild stress. Animal studies demonstrate that orally administered L-ornithine attenuates corticotropin-releasing factor (CRF)-induced distress vocalizations and anxiety-like behavior via GABA-A receptors in neonatal chicks. The human POMS evidence is modest in scale but the finding is replicated across studies measuring mood states.

L-theanine, a non-proteinogenic amino acid found in green tea, has multiple RCTs demonstrating anxiolytic and stress-reducing effects. At 200–400 mg/day it promotes alpha brain wave activity (relaxed alertness), increases GABA, and reduces cortisol. A systematic review of 9 RCTs found significant reductions in stress and anxiety, particularly under acute conditions.

L-tryptophan is the dietary precursor to serotonin and melatonin, with clinical evidence for reducing anxiety and improving mood. RCTs have demonstrated reduction in anxiety symptoms and improvement in sleep in depressed and anxious populations. It is reviewed among nutritional supplements for anxiety in peer-reviewed systematic literature. Tryptophan depletion studies confirm its role in serotonergic anxiety regulation.

Multiple randomized, double-blind, placebo-controlled trials have shown that L. gasseri CP2305 (heat-inactivated) significantly reduces anxiety scores in healthy adults under chronic stress. In one 4-week crossover study of medical students, daily CP2305 intake significantly improved anxiety and depressive mood versus placebo, and also suppressed salivary cortisol release. A longer 24-week RCT confirmed reductions in anxiety measured by the Spielberger State-Trait Anxiety Inventory.

L. paracasei PS23 and Lpc-37 have been studied in RCTs for anxiety and stress outcomes. A 6-week double-blind RCT of live PS23 in stressed office workers showed significant improvement in trait anxiety levels versus placebo. The gut-brain axis mechanism involves modulation of corticosterone, anti-inflammatory cytokines, and intestinal barrier integrity.

Several RCTs and a meta-analysis support L. plantarum strains reducing anxiety symptoms, including validated questionnaire scores, in stressed populations. Mechanisms involve the gut-brain axis, GABA production, and cortisol modulation.

L. rhamnosus HN001 reduced postpartum anxiety scores in a landmark 423-person double-blind RCT. The strain JB-1 consistently shows anxiolytic effects in animal models via GABA-dependent gut-brain signaling. Mechanistically, L. rhamnosus modulates the HPA axis and corticosterone response. Evidence is strongest for postpartum anxiety and stress-induced anxiety models.

Lavender, particularly its oral preparation (Silexan, 80 mg/day), is among the most extensively studied botanicals for anxiety. Multiple RCTs and a systematic review demonstrate significant anxiolytic effects in generalized anxiety disorder, mixed anxiety and depression, and anxiety-related insomnia. It modulates voltage-dependent calcium channels and serotoninergic and noradrenergic transmission.

Lemon essential oil (LEO) aromatherapy has demonstrated anxiolytic effects in clinical trials. A multi-centered, assessor-blinded RCT in 100 acute myocardial infarction patients found lemon inhalation significantly reduced anxiety scores on day 4 post-intervention compared to paraffin placebo. Citrus essential oils broadly show anxiolytic properties in multiple human clinical conditions.

Lemon balm (Melissa officinalis) has clinical evidence for reducing anxiety and associated symptoms. Its anxiolytic mechanism involves inhibition of GABA transaminase (increasing brain GABA levels) via rosmarinic acid. A meta-analysis of clinical trials showed lemon balm improved anxiety scores more than placebo. Used traditionally throughout Europe for centuries as a calming nervine.

Two human clinical studies show lemongrass essential oil (LGEO) inhalation reduces state anxiety. A 2025 RCT in dental patients undergoing scaling and root planing found LGEO aromatherapy improved anxiety scores and hemodynamic measures. An earlier controlled human study found brief exposure to lemongrass aroma reduced state anxiety and subjective tension, with full recovery from an anxiety-inducing task within 5 minutes.

Lily bulb (Bai He, Lilium brownii/lancifolium) has documented anxiolytic activity in preclinical models, attributed primarily to its saponins and polysaccharides. Classical TCM formulas containing lily bulb have been evaluated in clinical studies for anxiety associated with the 'Lily Disease' pattern. A 2026 ScienceDirect study found total saponins from lily bulb produced significant anxiolytic effects in ovariectomized mice under chronic stress. A systematic review in the Journal of Ethnopharmacology confirmed improvements in anxiety scores with Bai He Di Huang Tang.

Multiple lines of evidence support limonene's anxiolytic activity. Animal studies document effects via dopaminergic and GABAergic modulation through adenosine A2A receptors. A small clinical study in hospital patients undergoing a stressful bone marrow procedure found that ambient D-limonene-dominant essential oil significantly lowered self-reported anxiety (STAI-S), blood pressure, and heart rate versus placebo. A 2024 human RCT (Johns Hopkins) further showed vaporized D-limonene significantly reduced THC-induced anxiety ratings.

Multiple small clinical trials show Lion's Mane reduces anxiety scores in humans. An 8-week RCT in 77 overweight adults found a 33.2% improvement in anxiety versus baseline. A 4-week RCT in 30 menopausal women also demonstrated significant reductions. Evidence is consistent but limited by small sample sizes.

Clinical evidence suggests lithium reduces anxiety symptoms, particularly comorbid anxiety in mood disorders. A 2022 six-week open-label trial found significant anxiety reduction in bipolar depression patients on low-dose lithium, with over half reaching full remission of anxiety symptoms. Evidence for lithium orotate specifically is extrapolated from broader lithium research.

Neferine, a bisbenzylisoquinoline alkaloid from lotus seed embryos, has demonstrated anxiolytic effects in animal models comparable to diazepam without motor impairment. A small exploratory human study with Nelumbo nucifera extract showed clinically meaningful reductions in GAD-7 anxiety scores. Traditional Chinese medicine has long used lotus seed embryo for calming mental agitation.

Multiple preclinical studies show luteolin reduces anxiety-like behavior through suppression of neuroinflammation, HPA axis regulation, and monoamine modulation. Animal models of sleep deprivation, PTSD, and chronic stress all demonstrate significant anxiolytic effects. Human clinical evidence remains limited, with no standalone RCTs in anxious populations yet published.

Small RCTs in postmenopausal women show maca (3.5 g/day) reduces self-reported anxiety scores, independent of changes in estrogen or androgen levels. Flavonoids in maca are hypothesized to inhibit monoamine oxidase activity. Evidence is preliminary and limited to small trials in specific populations.

Magnesium is an essential mineral with multiple RCTs and systematic reviews supporting modest anxiolytic effects, particularly in individuals with low magnesium status. It acts as an NMDA receptor antagonist, reduces glutamate-mediated excitotoxicity, and supports GABA signaling. Systematic reviews consistently find positive effects in anxious, PMS, and mildly stressed populations, though effect sizes are variable.

Multiple human trials support magnolia bark's anxiolytic effects. A double-blind RCT (Relora® blend, n=56) reduced salivary cortisol by 18% and improved multiple mood-state scores versus placebo. A separate pilot RCT in premenopausal women showed state anxiety scores fell by an average of 14.3 points vs. 7.6 in placebo over six weeks. The active mechanism involves honokiol acting as a positive allosteric modulator of GABA-A receptors.

Magnolol is a bioactive lignan from Magnolia bark (Magnolia officinalis) with anxiolytic activity demonstrated in preclinical and some human studies. It modulates GABA-A receptors and serotonin signaling. A PMC systematic review on anxiety supplements explicitly includes Magnolia/Phellodendron bark extracts (containing magnolol) among reviewed treatments. Relora, a combination of Magnolia and Phellodendron, has some human trial evidence for cortisol and anxiety reduction.

A 2023 RCT (n=57 ICU nurses) found that inhaling 3% marjoram essential oil for 2 hours significantly reduced state anxiety and perceived stress scores compared to a control oil. Traditional herbalism has long classified marjoram as anxiolytic, attributing this to its volatile terpene constituents modulating central nervous system activity.

Melatonin has demonstrated anxiolytic effects in multiple clinical contexts, particularly preoperative anxiety and sleep-related anxiety. A review in PMC documents its clinical anxiolytic action across several conditions. It acts via MT1 and MT2 melatonin receptors and modulates the HPA axis and circadian rhythm-related anxiety pathways. It is widely reviewed in mainstream clinical pharmacology for this indication.

Motherwort has small human clinical evidence supporting anxiolytic effects. A pilot study (1200 mg/day oil extract, 50 hypertensive patients) found significant improvement in anxiety and emotional lability scores. Animal studies attribute this to iridoid and alkaloid fractions acting on GABAergic pathways. Germany's Commission E has authorized it for cardiac complaints of nervous origin, which includes anxiety-driven palpitations.

NAC has preliminary clinical evidence for anxiety disorders, primarily through its modulation of glutamate neurotransmission and reduction of oxidative neuroinflammation. A systematic review of NAC in psychiatry and neurology classified anxiety among disorders with preliminary evidence requiring larger confirmatory studies. A 2025 narrative review similarly noted limited but suggestive anxiolytic effects in clinical populations.

Naringenin (naringin's aglycone) exerts anxiolytic effects in rat models by modulating monoaminergic systems, inhibiting MAO-A, and suppressing neuroinflammation. A 2025 rat study found naringenin at 100 mg/kg significantly ameliorated anxiety-like behaviors and restored neurotransmitter homeostasis. Evidence is entirely preclinical.

Preclinical studies have documented anxiolytic effects of C. rotundus extracts in animal models. The Pharmaceutical and Biomedical Research review (2021) describes in vivo studies evaluating anxiolytic and cognitive effects. The plant's sedative action in CNS models is also documented, consistent with anxiolytic properties.

Omega-3 fatty acids (EPA and DHA) have a 2024 systematic review and dose-response meta-analysis of 23 RCTs (n=2,189) demonstrating significant reduction in anxiety symptoms, with the greatest benefit at ≥2 g/day. Mechanisms include anti-inflammatory activity, BDNF modulation, and HPA axis regulation. Evidence quality is rated low to moderate.

Ruscogenin, a major steroidal saponin from Ophiopogon japonicus, has been shown to exert anti-anxiety effects in animal models of chronic pain-induced anxiety by regulating TLR4-mediated NFκB/MAPK/NLRP3 signaling. No human clinical trials exist for anxiolytic effects of O. japonicus.

Clinical trials demonstrate that inhalation of Citrus sinensis essential oil reduces anxiety in patients awaiting dental treatment and in healthy volunteers exposed to anxiogenic situations. Oral C. aurantium preparations also show anxiolytic effects. The evidence base is promising but methodologically limited, and further well-designed trials are warranted.

Platycladus orientalis seeds (Bai Zi Ren) have a documented traditional use for anxiety and nervous restlessness in TCM. Preclinical research using plant-derived extracellular vesicles from P. orientalis leaves has demonstrated anxiolytic effects in rodent models, modulating serotonin (5-HT) and GABA neurotransmitter pathways. No human clinical trials exist, but laboratory evidence supports a plausible mechanism.

P. foetida exhibits sedative-anxiolytic activity in preclinical rodent models. Evaluation of analgesic and sedative-anxiolytic potential using leaf extract has been published. The anxiolytic activity is pharmacologically documented alongside anticonvulsant properties relevant to the nervous system.

Passionflower (Passiflora incarnata) has been studied in randomized controlled trials for anxiety and GAD. One landmark pilot RCT found passionflower comparable in efficacy to oxazepam for GAD with fewer adverse effects on job performance. It is thought to act as a partial GABA-A agonist. Both traditional Western and Ayurvedic medical systems have used it as a nervine sedative.

Multiple clinical trials demonstrate that peppermint oil aromatherapy reduces state anxiety in clinical settings, including cardiac and ICU patients. A randomized placebo-controlled trial in cardiac emergency patients found measurable anxiety reduction using the Spielberger State-Trait Anxiety Inventory. A separate clinical trial in ICU myocardial infarction patients found inhalation of 0.2 ml peppermint oil reduced depression and anxiety scores on the DASS-21 scale. However, a PMC systematic review notes that current data do not fully support peppermint for anxiety disorders equivalent to established herbs like valerian.

The Relora blend (Magnolia + P. amurense) significantly reduced transitory state anxiety in a 2008 pilot double-blind RCT in premenopausal women. Berberine from P. amurense has demonstrated anxiolytic effects in rodent stress models including the elevated plus maze test. P. amurense is documented in both TCM and traditional Japanese medicine as an anxiety remedy.

Polygalasaponins from P. tenuifolia root have demonstrated anxiolytic activity in multiple preclinical animal models, reducing anxiety-like behaviors via modulation of the central noradrenergic system and BDNF upregulation. TCM has used Yuan Zhi for centuries to calm the mind and ease restlessness. Human clinical evidence remains limited, but the preclinical mechanistic work is well-documented in peer-reviewed literature.

Lower CSF and serum pregnenolone levels have been documented in generalized anxiety disorder and social phobia. Clinical trials in substance-use-disorder populations show pregnenolone reduces stress- and cue-induced anxiety. Pregnenolone's anxiolytic action is mediated through its downstream metabolite allopregnanolone, which positively modulates GABA-A receptors.

Progesterone metabolizes in brain tissue to allopregnanolone (ALLO), which enhances GABA-A receptor activity and produces anxiolytic and sedative effects in humans. Multiple human studies have found a positive association between progesterone levels and anxiety measures, with the relationship being bidirectional: ALLO can reduce anxiety, while rapid fluctuations or withdrawal of progesterone may provoke it. Evidence is strongest for cycle-related anxiety in premenopausal women.

A 2005 double-blind RCT (Tang et al., J Medicinal Food) in 132 neurasthenia patients found reishi polysaccharide extract significantly reduced anxiety-related fatigue and improved wellbeing versus placebo. A 2026 multi-mushroom RCT including reishi demonstrated significant cortisol and anxiety reductions over 12 weeks. Preclinical data point to HPA-axis modulation and anti-inflammatory cytokine regulation as mechanisms. Evidence is promising but limited by small trials and use of neurasthenia rather than DSM-5 anxiety diagnoses.

Multiple placebo-controlled RCTs have tested Relora® directly for anxiety. A 2008 pilot RCT (Kalman et al., Nutrition Journal, n=40 overweight premenopausal women) found Relora reduced transitory state anxiety on the Spielberger STATE questionnaire versus placebo, though it did not reduce trait (long-standing) anxiety. A 2006 FASEB-reported RCT showed Spielberger Trait and Anxiety Index Total scores improved significantly and by twice as much with Relora as with placebo (p=0.047). Evidence is promising but limited to small pilot studies.

Rhodiola rosea is a well-characterized adaptogen with multiple clinical trials demonstrating reductions in stress, anxiety, and burnout. Its active rosavins and salidroside modulate the HPA axis, inhibit monoamine oxidase, and regulate cortisol. Proof-of-concept studies confirm safety and modest antidepressant/anxiolytic effects, and combination with saffron has shown significant improvements in anxiety in a 2025 placebo-controlled RCT.

Multiple RCTs and a meta-analysis of 32 RCTs confirm that Rosa damascena (in aromatherapy or oral extract form) significantly reduces state anxiety scores in adults across diverse clinical settings. A 2021 meta-analysis pooled 32 publications and reported a large effect size (SMD: −1.74). A 2025 RCT in menopausal women (n=82, 500 mg oral extract) showed anxiety scores drop from 14.6 to 6.2 vs. minimal change in placebo (p<0.001).

Multiple human clinical trials show rosemary reduces anxiety scores in healthy students and patients with major depressive disorder. A randomized, double-blind, placebo-controlled crossover trial also found that rosemary extract significantly improved trait anxiety on the STAI and reduced state anxiety after a single dose. Evidence points to rosmarinic acid modulating oxidative stress and inflammatory pathways involved in anxiety.

Rosmarinic acid (RA), primarily through RA-rich lemon balm (Melissa officinalis) extracts, has shown anxiolytic effects in multiple human clinical trials. A 2022 randomized, double-blind, placebo-controlled trial found rosemary capsules (containing quantified RA) significantly reduced Hospital Anxiety and Depression Scale anxiety subscale scores in patients with major depressive disorder over 8 weeks. Preclinical work indicates RA modulates the HPA axis and BDNF signaling to reduce anxiety-like behavior.

A single RCT found that 800 mg of royal jelly (RJ) daily for 12 weeks improved anxiety scores in postmenopausal women. Preclinical work implicates 10-hydroxy-trans-2-decenoic acid (10-HDA) and modulation of BDNF signaling as mechanisms. Evidence is limited to one human trial and animal models.

Saffron (Crocus sativus) has multiple RCTs demonstrating anxiolytic and antidepressant effects, with efficacy comparable to standard antidepressants such as fluoxetine in some trials. Active constituents crocin and safranal modulate serotonin, dopamine, and norepinephrine reuptake. A systematic review identified saffron among herbs with the strongest evidence base for anxiety, with positive results in all 3 available RCTs at time of review.

A double-blind, placebo-controlled crossover RCT found that oral sage (300 and 600 mg dried leaf) reduced anxiety before and after a psychological stressor battery in healthy adults. Mood improvements including calmness were also reported. The mechanism involves cholinesterase inhibition and enhanced cholinergic tone.

Multiple human studies support sceletium's anxiolytic potential. A pharmaco-fMRI RCT (n=16) showed a single 25 mg dose of Zembrin® attenuated amygdala reactivity to fearful stimuli and reduced amygdala-hypothalamus coupling. A 2020 placebo-controlled study found 25 mg Zembrin® significantly lowered subjective anxiety and blunted heart-rate response during a stress task. A 2023 systematic review/meta-analysis of four RCTs (n=117) found mixed pooled results, with no statistically significant group-level reduction in anxiety scores overall.

Animal studies show schisandra lignans reduce stress-induced anxious behavior, lower brain MAO levels, and normalize plasma cortisol via HPA axis modulation. In vitro studies confirm anti-anxiety activity. In TCM, schisandra has been used to calm the shen (spirit) and relieve anxiety-driven insomnia.

Albizia julibrissin has well-documented anxiolytic activity supported by multiple preclinical studies. Key constituents including julibroside C1 and the lignan SAG act via GABA-A receptor activation and HPA axis modulation. The plant has centuries of use in TCM for anxiety and is among the most studied herbs in this area.

Preclinical studies demonstrate anxiolytic activity for S. indicus hydroalcoholic extract in rodent models. At low doses (100 mg/kg), the extract increased open-arm entries in the elevated plus maze test, indicating anxiolytic effect. Traditional use in Ayurveda for mental illness aligns with these findings.

St. John's Wort (Hypericum perforatum) is primarily evidence-based for depression but has mixed evidence for anxiety. Systematic reviews show approximately 50% of studies reporting positive results for anxiety symptoms. Its active compounds (hyperforin, hypericin) inhibit serotonin, dopamine, and noradrenaline reuptake. German Commission E and EMA approve it for mild-to-moderate depression and some anxiety indications.

The 20-hydroxyecdysone-enriched fraction from P. glomerata roots significantly reduced anxiety-related behaviors in mice at 30 mg/kg (Franco et al., 2021). Traditional use of suma by indigenous Brazilians as a calming tonic aligns with this finding.

Preclinical animal studies demonstrate anxiolytic effects of A. calamus extracts, and a small open-label human trial (n=33) using 500 mg twice daily of a hydroethanolic extract over 60 days reported reductions in anxiety ratings. The active constituents α- and β-asarone are thought to modulate GABAergic pathways. No large randomized controlled trials exist.

Taurine modulates inhibitory neurotransmission by acting at GABA-A and glycine receptors, producing anxiolytic effects in animal models. Clinical observational data link altered taurine metabolism to anxiety states. Human clinical trial data remain limited, but preclinical evidence is mechanistically robust.

MgT, which delivers threonic acid to the brain, has shown anxiolytic effects in both preclinical and human studies. Animal work showed MgT enhances fear extinction in the prefrontal cortex and amygdala without erasing fear memory. A human RCT found significant reduction in Hamilton Anxiety scores with MgT treatment in cognitively impaired older adults.

T. cordifolia ameliorated anxiety-like behavior in acutely sleep-deprived rats, and its extracts have been reported in PubMed-indexed reviews as anti-anxiety agents. Multiple studies document modulation of brain antioxidant and monoamine systems relevant to anxiety.

Human RCT data show Tongkat Ali supplementation reduces tension-anxiety subscores on validated psychological scales. The Talbott et al. (2013) placebo-controlled trial found reduced tension scores (−11%) in moderately stressed subjects. A Japanese RCT found tension-anxiety in the Tongkat Ali group was lower than placebo with marginal significance. Animal studies additionally showed anxiolytic effects comparable to diazepam. Evidence is preliminary but human data exist.

Multiple RCTs and meta-analyses indicate curcumin supplementation significantly reduces anxiety symptoms. A 2024 meta-analysis of 8 RCTs (567 participants) found a pooled SMD of −1.56 (p<0.001) for anxiety reduction. A 2025 systematic review of 15 RCTs (1,123 participants) also reported significant anxiolytic effects (SMD: −0.22, p=0.01). Evidence strength is moderated by study heterogeneity and small sample sizes.

Valerian (Valeriana officinalis) has a long traditional history as a sedative and anxiolytic. Clinical evidence is mixed: some trials show significant anxiolytic effects while others find no advantage over placebo. It appears to work via GABAergic mechanisms, with valerenic acid acting at GABA-A receptors. The German Commission E approves it for nervous unrest and sleep disorders.

Human clinical evidence supports vanilla's anxiolytic effects primarily via aromatherapy. A study at Memorial Sloan-Kettering found that patients exposed to a vanilla-like (heliotropin) fragrance during MRI procedures experienced 63% less anxiety than controls. Animal studies also show vanillin can reduce anxiety-like behaviors. No oral dosing trials in humans have been conducted.

Clinical trials have tested thiamine supplementation in anxiety-related conditions, with some positive signals. A triple-blind RCT in women with polycystic ovary syndrome found 300 mg/day of thiamine for four weeks reduced anxiety and somatic symptoms. Systematic reviews of B vitamins for anxiety show mixed, modest effects, and results depend heavily on baseline deficiency status.

Vitamin B12 deficiency is clinically associated with neuropsychiatric symptoms including anxiety, linked to disrupted one-carbon metabolism and impaired neurotransmitter synthesis. Observational data show low B12 correlates with anxiety presentations, but Mendelian randomization studies have not confirmed a direct causal effect. The relationship is strongest in the context of frank deficiency rather than supplementation in replete individuals.

Animal studies from the 1970s–80s established that niacinamide binds to benzodiazepine receptors with mild anxiolytic-like effects. Case series and clinical observations have suggested reduced anxiety in some individuals taking high-dose niacinamide. Evidence remains largely preclinical and case-based; large-scale RCTs are absent, but biological plausibility is documented in the literature.

High-dose vitamin B6 supplementation has been shown in a double-blind RCT to reduce self-reported anxiety in young adults, with the proposed mechanism being enhancement of GABAergic inhibitory neurotransmission. Cross-sectional data additionally associate lower B6 intake with higher anxiety risk in women. Evidence is preliminary and limited to non-clinical populations.

Multiple randomized controlled trials have documented anxiolytic effects of Bacopa monnieri in humans. A 12-week RCT in elderly participants showed significant reductions in combined state and trait anxiety scores compared to placebo. Clinical doses of 300–600 mg standardized extract daily are typically used, with effects emerging after about 12 weeks.

Withanolides are the primary bioactive steroidal lactones of ashwagandha (Withania somnifera) responsible for its anxiolytic and adaptogenic effects. Clinical trials of ashwagandha extract standardized to withanolide content demonstrate significant reductions in anxiety, stress, and cortisol. They modulate GABA-A receptors, inhibit cortisol secretion, and regulate HPA axis activity.

Animal studies demonstrate that A. millefolium hydroalcoholic extract produces anxiolytic-like effects in elevated plus-maze and marble-burying tests, acting through GABA-A/benzodiazepine receptor modulation. Traditional Brazilian folk use specifically employs yarrow infusions for 'calmness.' No human clinical trials on anxiety exist.

Yohimbine has been investigated as an adjunct to exposure-based therapy for anxiety disorders and phobias, with mixed clinical results. Some randomized controlled trials show it can accelerate fear extinction and reduce self-reported anxiety when given prior to exposure sessions. Other trials, notably in virtual-reality treatment of flight phobia, found no benefit over placebo. At the same time, yohimbine itself can provoke anxiety as a side effect via noradrenergic stimulation.

In Traditional Chinese Medicine (TCM), amber (Hu Po) is a classical sedative herb used to calm the mind and settle fright, indicated for anxiety, palpitations, and restlessness. Animal studies suggest succinic acid has CNS-inhibitory effects. No human clinical trials exist for anxiety specifically.

Bacopa monnieri (Brahmi) has been used for centuries in Ayurvedic medicine for anxiety, mental agitation, and cognitive enhancement. While clinical RCTs primarily show cognitive benefits, traditional use for nervous anxiety is well established. Human trial evidence for anxiety specifically is preliminary and inconsistent. It modulates acetylcholinesterase, serotonin, and cortisol.

Baikal skullcap has a long history of use in TCM for anxiety, and preclinical evidence shows its active flavonoids baicalin and baicalein interact with the GABAergic system similarly to conventional anxiolytics. Rodent studies demonstrate reduced anxiety-like behaviors. However, direct randomized controlled trials in humans specifically for anxiety as a primary endpoint remain absent.

Black spruce essential oil is used in aromatherapy for anxiety and stress relief. Its bornyl acetate content is associated with calming and sedating properties. Phytoncide exposure from conifers has been shown in human studies to shift autonomic balance and reduce stress hormones, supporting this traditional use.

Anxiety is listed among the traditional applications of butterbur in NCCIH government documentation and multiple pharmacognosy databases. No clinical or pharmacological evidence specifically supports an anxiolytic mechanism, and no human trials have assessed this indication.

Convolvulus pluricaulis (Shankhpushpi) is a primary Ayurvedic medicinal plant for anxiety and nervous disorders, with traditional use spanning thousands of years. Alkaloids and flavonoids modulate GABA and serotonin pathways. Preclinical studies confirm anxiolytic effects. It is listed in the Ayurvedic Pharmacopoeia of India for mental health. Human RCTs are limited.

Preclinical rodent and insect models show cowage seed extract has anxiolytic effects, likely through GABAergic modulation and reduced cortisol. A human study on infertile men demonstrated significantly reduced state-anxiety scores after 3 months of 5 g/day seed powder. No dedicated anxiety RCT exists in humans.

Damiana (Turnera diffusa) is a traditional Mexican and Central American plant used for anxiety, depression, nervousness, and as a tonic. Active flavonoids may modulate progesterone receptors and GABA pathways. It is included in historical pharmacopeias and ethnobotanical literature for its calming and nervine effects. Modern clinical evidence is limited.

Jamaican dogwood (Piscidia erythrina) has a long traditional history of use for anxiety, fear, and nervous excitability. Animal studies support anxiolytic activity, but no controlled human trials exist. It is listed in traditional herbalism references including the British Herbal Pharmacopoeia for this indication.

Eleuthero (Eleutherococcus senticosus, Siberian ginseng) is classified as an adaptogen with traditional use in Russian and Chinese medicine for stress, nervous exhaustion, and anxiety-like states. Clinical trials support anti-fatigue and stress-adaptive effects; clinical evidence specifically for anxiety as a diagnosed condition is limited. Active eleutherosides modulate HPA axis and sympathoadrenal response.

Panax ginseng has a 2,000-year tradition in Chinese medicine for restoring vitality, reducing stress, and calming the mind. Modern evidence suggests anxiolytic effects via HPA axis modulation, serotonergic activity, and anti-inflammatory pathways. Clinical evidence for primary anxiety disorder is limited, but multiple trials show reduction in stress-related anxiety symptoms. Ginsenosides are the primary bioactive compounds.

In TCM, Shi Jue Ming (abalone shell) is documented for calming conditions attributed to Liver Heat or Liver Yang rising, including anxiety, irritability, and palpitations. There are no human clinical trials evaluating haliotis specifically for anxiety.

Hawthorn has a documented traditional use in European and TCM herbalism for anxiety, nervousness, and palpitations associated with mild anxiety. A double-blind RCT of a fixed combination containing hawthorn, California poppy, and magnesium reduced mild-to-moderate anxiety versus placebo, but hawthorn's independent contribution cannot be isolated. NCCIH states the evidence on hawthorn for anxiety remains unclear.

Hops (Humulus lupulus) strobiles have a centuries-long tradition in European herbal medicine for anxiety, nervous tension, and insomnia. Clinical evidence is primarily from combination preparations (with valerian). Active methylbutenol and flavonoids modulate GABA-A receptors. German Commission E and ESCOP recognize hops for nervous tension and sleep disorders.

Hyssop is traditionally prescribed as a nervine herb for anxiety and hysteria in Western herbal medicine. It is listed as a sedative and nervine tonic in classical herbal references. Animal studies suggest CNS-modulating activity via the GABAergic system.

Jatamansi (Nardostachys jatamansi) is a classical Ayurvedic herb used for anxiety, hysteria, epilepsy, and mental disorders. It modulates GABA, serotonin, and norepinephrine levels. Preclinical studies confirm anxiolytic and CNS-depressant activity. Traditional Ayurvedic texts describe it as a premier 'medhya' (mind-calming) herb. Clinical human trial data are limited.

Jujube (Ziziphus jujuba) and its seed (Suan Zao Ren) have a well-established role in traditional Chinese medicine for anxiety, insomnia, palpitations, and nervous disorders. The seeds contain jujubosides and saponins that modulate GABA and serotonin pathways. Clinical studies support sedative and anxiolytic effects in stressed populations. Use in TCM for anxiety spans over 2,000 years.

Jujubosides are the primary saponin bioactives of Ziziphus jujuba seed (Suan Zao Ren) responsible for anxiolytic and sedative effects. They inhibit glutamate-induced neuronal excitation and modulate hippocampal GABA activity. Used for 2,000+ years in TCM for anxiety and insomnia, they are recognized in the Chinese Pharmacopoeia.

Lobelia has been traditionally used to ease anxiety and panic attacks, primarily in Eclectic and Native American medicine, based on its CNS depressant and relaxant effects at low doses. ScienceDirect's Lobelia inflata overview notes the herb "has been used to ease anxiety and panic attacks." No human clinical trials have specifically evaluated this use.

In TCM, Lophatherum leaf is used for heat-related emotional disturbance including agitation and restlessness, which conceptually overlaps with anxiety. Classical texts document its spirit-calming (Shen-calming) function. There is no pharmacological or clinical evidence for anxiolytic activity in the modern sense.

Mimulus is one of Dr. Edward Bach's 38 flower remedies, designated since the 1930s as the specific remedy for anxiety and fear arising from known, identifiable causes. Traditional practitioners use it for everyday fears such as public speaking, illness, or specific phobias. Controlled clinical trials of Bach flower remedies have not demonstrated efficacy beyond placebo, so the evidence base remains purely traditional.

Peppermint is used in traditional herbal medicine as a mild nervine and anxiolytic. Animal studies suggest menthol has dose-dependent anxiolytic effects involving dopamine pathways. Human clinical evidence specifically for anxiety is limited, though menthol's calming, cooling sensory effects are well-documented.

A. vulgaris is recorded in Ayurvedic root preparations and the European Pharmacopoeia homeopathic listings for anxiety and nervous disorders. Related Artemisia species contain constituents (ursolic acid, oleanolic acid, carnosol) that modulate GABA-A receptors via the benzodiazepine binding site, demonstrating anxiolytic effects in rodent models. No human clinical trials on anxiety for A. vulgaris specifically exist.

Muira puama's bark and roots have been used traditionally for anxiety and nervous tension in Amazonian and European herbal medicine. EBSCO's authoritative database lists anxiety among its documented traditional therapeutic uses. Notably, at least one preclinical study has reported anxiogenic (anxiety-promoting) rather than anxiolytic effects, making scientific support for anxiety relief absent.

Mulungu (Erythrina mulungu/verna) is a traditional Brazilian medicinal plant widely used for anxiety, agitation, insomnia, and nervous conditions. Alkaloids (erythravine, alpha-hydroxyerythravine) modulate GABA-A receptors. Animal studies demonstrate robust anxiolytic effects, and it has long been used as a natural tranquilizer in Brazilian folk medicine. Human RCT data are limited.

Ophiopogon root is classically prescribed in TCM for anxiety and heart-related restlessness from yin deficiency and heart fire. Traditional Kampo and TCM sources consistently include anxiety-like agitation among its indications. Sedative and calming properties are mentioned in historical texts. No human anxiolytic clinical trials with O. japonicus alone exist.

Gamma-oryzanol (γ-oryzanol), the principal bioactive of Oryza sativa bran, has been approved in Japan for mild anxiety and has shown antianxiety effects in animal models. β-Sitosterol, another rice bran constituent, similarly ameliorates anxiety-like behavior in rodents by modulating monoamine neurotransmitters. Human clinical evidence remains limited.

Peach leaf is classified as a mildly sedative nervine in Western herbalism and folk traditions, used for anxiety, restlessness, and nervous tension. Multiple herbalism sources document this application. No pharmacological or clinical evidence exists.

Peony (Paeonia lactiflora) has a long history of use in Traditional Chinese Medicine to calm the spirit and reduce irritability and restlessness. Preclinical studies show paeoniflorin may modulate serotonin transporters and neurotransmitter systems with anxiolytic-like effects, but robust human clinical trials are absent.

Perillae Herba is referenced in traditional oriental herbal medicine for affective disorders including anxiety. In TCM and Ayurvedic traditions, perilla is used for its calming and nervine properties. Preclinical data on rosmarinic acid's monoaminergic and antioxidant effects are consistent with anxiolytic potential, but human clinical evidence is absent.

Polygala root has documented traditional use in TCM for 'palpitations with anxiety' and restlessness. Preclinical animal studies demonstrate anxiolytic effects, but robust human clinical trials specifically for anxiety are lacking. The herb is listed in the Chinese Pharmacopoeia for such neuropsychiatric indications.

Poppy—particularly California poppy (E. californica) and P. rhoeas—has documented traditional use as an anxiolytic nervine. GABAergic alkaloids in California poppy provide a plausible mechanism. Preclinical (animal) data support anxiolytic activity, but robust human RCT evidence is currently absent.

Preclinical studies including behavioral tests in rodents show purslane extracts reduce anxiety, with neuroprotective and anxiolytic mechanisms proposed. Pharmacological reviews document anxiolytic properties. No human RCTs for anxiety as a primary endpoint were identified, placing the evidence in the traditional and preclinical category.

A 2022 PMC review and survey (n=1,074 Saudi participants) found over 55% used safflower for anxiety/depression, with high self-reported efficacy. Preliminary in vitro and in vivo studies support anxiolytic activity. No high-quality human RCTs exist for anxiety as a primary endpoint.

Schisandrins are the primary bioactive lignans of Schisandra chinensis, an adaptogen with long traditional use in Chinese and Russian medicine for stress, nervous exhaustion, and anxiety. They modulate the HPA axis, reduce cortisol, and have serotonergic and dopaminergic activity. Russian clinical studies support stress-adaptive and anxiolytic-adjacent effects.

The dried sclerotium of Poria cocos has been used in TCM for centuries to calm the mind and ease mental unrest. Animal studies show extracts modulate GABA-A receptor activity, a mechanism shared with anxiolytic drugs. Human clinical data specifically for anxiety remain lacking.

Shankhpushpi (Convolvulus pluricaulis) is a classical Ayurvedic 'medhya rasayana' (brain tonic) used specifically for anxiety, mental tension, and nervous disorders. It modulates GABAergic and serotonergic systems. Preclinical studies confirm anxiolytic effects. It is referenced in multiple Ayurvedic texts for anxiety and nervous debility. Human RCT evidence is limited.

Skullcap (Scutellaria lateriflora) is a traditional North American nervine used for anxiety, nervous tension, and hysteria since the 18th century. Active flavonoids (baicalin, scutellarein) modulate GABA-A receptors. It is listed among reviewed anxiolytic herbs in the PMC systematic review literature. Clinical RCT evidence for anxiety specifically is limited.

Soursop is cited in pharmacological literature as possessing anxiolytic properties, and its traditional use as a nervine and sedative supports a relationship with anxiety. Pre-clinical evidence and alkaloid chemistry provide biological plausibility.

Squawvine is listed in folk medicine sources as a traditional remedy for anxiety and nervous exhaustion, attributed to its mild sedative and nervine tonic properties. Eclectic texts describe it as a nervous tonic and restorative for irritability and debility. No clinical evidence exists.

Star of Bethlehem is one of five ingredients in Bach Rescue Remedy, traditionally indicated for acute shock, fright, and associated anxiety. Systematic reviews of Bach flower remedies (Thaler et al., BMC Complement Med 2009; Ernst, Swiss Med Wkly 2010) found no evidence of benefit over placebo in controlled trials for anxiety. The indication rests entirely on Dr. Edward Bach's 1930s system, in which this flower essence is assigned to states of acute distress and shock-induced anxiety.

Preclinical studies show MP seed extracts exert anxiolytic effects in rodent models (elevated plus maze, light-dark box), linked to GABAergic neurotransmission enhancement. Traditional Indian medicine uses MP for nervous disorders. The 2023 in vivo histopathological study confirmed GABA elevation and reduced anxiety markers in mice. No human clinical trial has been conducted specifically for anxiety.

Wood betony is one of Europe's most documented nervine herbs, historically prescribed in tincture or tea form for anxiety, nervous tension, and overactive mental states. The British Herbal Pharmacopoeia lists it for nervousness and hysteria. All evidence remains traditional and herbal-clinical, with no controlled human trials.